マイコプラズマ検査市場 - 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、用途別、エンドユーザー別、地域別、競合別、2020年～2030年

マイコプラズマ検査の世界市場は2024年に10億9,070万米ドルとなり、2030年までのCAGRは13.45%で堅調な成長が予測されています。

世界のマイコプラズマ検査市場は、診断および感染症管理という広範な分野の中で、ダイナミックかつ急速に発展している分野です。マイコプラズマは細胞壁を持たないことで知られる細菌属で、ヒト、動物、細胞培養を含む様々な宿主生物に感染します。マイコプラズマの汚染は研究、バイオ医薬品製造、臨床診断に重大な脅威をもたらすため、マイコプラズマ検査は品質管理と安全性保証に不可欠な要素となっています。

市場概要
予測期間	2026年～2030年
市場規模：2024年	10億9,070万米ドル
市場規模：2030年	23億3,062万米ドル
CAGR：2025年～2030年	13.45%
急成長セグメント	キット・試薬
最大市場	北米

主要な市場促進要因

バイオ医薬品・バイオテクノロジー産業の成長

主要な市場課題

開発途上地域におけるコスト制約

主要市場動向

分子診断の急速な普及

世界のマイコプラズマ検査市場における重要な動向の一つは、分子診断、特にポリメラーゼ連鎖反応（PCR）ベースの方法の急速な採用です。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 マイコプラズマ検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（機器、キット、試薬）
  • 技術別（PCR、ELISA、酵素法、DNA染色、その他）
  • 用途別（細胞株試験、バイオプロダクション試験、その他）
  • エンドユーザー別（学術研究機関、細胞バンク、契約調査機関、製薬・バイオテクノロジー企業、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のマイコプラズマ検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のマイコプラズマ検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋のマイコプラズマ検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のマイコプラズマ検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのマイコプラズマ検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のマイコプラズマ検査市場：SWOT分析

第14章 競合情勢

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Mycoplasma Testing Market was valued at USD 1090.70 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 13.45% through 2030. The Global Mycoplasma Testing Market is a dynamic and rapidly evolving sector within the broader field of diagnostics and infectious disease management. Mycoplasma, a genus of bacteria known for their lack of a cell wall, can infect various host organisms, including humans, animals, and cell cultures. Mycoplasma contamination poses a significant threat to research, biopharmaceutical manufacturing, and clinical diagnostics, making mycoplasma testing an essential component of quality control and safety assurance.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1090.70 Million
Market Size 2030	USD 2330.62 Million
CAGR 2025-2030	13.45%
Fastest Growing Segment	Kits and Reagents
Largest Market	North America

Key Market Drivers

Rising Biopharmaceutical and Biotechnology Industries

The rapid expansion of the biopharmaceutical and biotechnology industries is a key driver of the Global Mycoplasma Testing Market. Over the past few years, the number of FDA-registered manufacturing facilities in the U.S. producing human-use medicines, along with their associated testing, labeling, and packaging operations, has surged by more than 50%. Biopharmaceutical companies are actively investing in new construction, facility expansions, and technology upgrades to support the production of next-generation therapies, ensuring a robust and scalable supply chain for advanced treatments across the country. These industries rely heavily on cell culture-based production processes, where contamination can compromise product integrity, regulatory compliance, and patient safety. Mycoplasma, a frequent and insidious contaminant, necessitates stringent testing protocols to ensure the purity and efficacy of biopharmaceutical products. The rising investments, increasing adoption of biologics, and growing need for quality control in biotech processes directly fuel the demand for mycoplasma testing. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilars, are revolutionizing modern medicine. These products rely on mammalian cell cultures for production, making them highly susceptible to mycoplasma contamination. The growing adoption of biologics for treating chronic diseases, including cancer, autoimmune disorders, and infectious diseases, necessitates stringent contamination control measures. As patents for biologic drugs expire, biosimilar manufacturers must comply with regulatory guidelines for mycoplasma testing to ensure their products meet the same safety and efficacy standards as originator biologics. With global sales of biologics projected to surpass traditional pharmaceuticals, mycoplasma testing has become an integral part of quality assurance in drug development and production.

Key Market Challenges

Cost Constraints in Developing Regions

One of the significant challenges in expanding the mycoplasma testing market is the cost associated with acquiring and implementing testing solutions. In developing regions with limited healthcare budgets, investing in expensive mycoplasma testing equipment and reagents can be prohibitive.

Many developing countries allocate a substantial portion of their healthcare budgets to basic healthcare needs like vaccinations and infectious disease control. This leaves limited resources for advanced diagnostic technologies, including mycoplasma testing. Establishing a mycoplasma testing infrastructure, including purchasing specialized equipment and training personnel, requires a considerable initial investment that some regions may struggle to afford. Continuous testing relies on a steady supply of costly reagents and consumables, which can be a financial burden for healthcare facilities in resource-constrained areas.

Key Market Trends

Rapid Adoption of Molecular Diagnostics

One significant trend in the Global Mycoplasma Testing Market is the rapid adoption of molecular diagnostics, particularly Polymerase Chain Reaction (PCR)-based methods.

Molecular diagnostic techniques, such as PCR, offer unparalleled sensitivity and specificity in detecting mycoplasma DNA. They can identify even low levels of contamination quickly and accurately. Molecular tests provide rapid results, often within hours, compared to traditional culture-based methods that can take days or even weeks. This speed is crucial in maintaining the efficiency of biopharmaceutical production and research. Automated molecular testing platforms allow for high throughput, making them suitable for large-scale testing in biopharmaceutical manufacturing facilities. PCR-based methods reduce the risk of false positives associated with traditional culture-based techniques, as they do not rely on the growth of mycoplasma cells.

Key Market Players

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

Report Scope:

In this report, the Global Mycoplasma Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mycoplasma Testing Market, By Product:

• Instruments
• Kits and Reagents

Mycoplasma Testing Market, By Technology:

• PCR
• ELISA
• Enzymatic Methods
• DNA Staining
• Other

Mycoplasma Testing Market, By Application:

• Cell Line Testing
• Bioproduction Testing
• Other

Mycoplasma Testing Market, By End-User:

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Mycoplasma Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.

Available Customizations:

Global Mycoplasma Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Mycoplasma Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Kits and Reagents)
  • 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
  • 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
  • 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Mycoplasma Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mycoplasma Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Mycoplasma Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Mycoplasma Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Mycoplasma Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mycoplasma Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Mycoplasma Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Mycoplasma Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Mycoplasma Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Mycoplasma Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Mycoplasma Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Mycoplasma Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Mycoplasma Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Mycoplasma Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Mycoplasma Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Mycoplasma Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Mycoplasma Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Mycoplasma Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Mycoplasma Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Mycoplasma Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Mycoplasma Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Mycoplasma Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Mycoplasma Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Mycoplasma Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Mycoplasma Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Agilent Technologies Inc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. ATCC
• 14.3. Bionique Testing Laboratories Inc.
• 14.4. Charles River Laboratories International Inc.
• 14.5. Lonza Group Ltd
• 14.6. Merck KGaA
• 14.7. Bionique Testing Laboratories Inc.
• 14.8. PromoCell GmbH
• 14.9. Thermo Fisher Scientific Inc.
• 14.10.Sartorius AG

15. Strategic Recommendations

16. About Us & Disclaimer